A5064804402- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cervical Cancer and HPV Research
- Cancer and Skin Lesions
- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy
- PI3K/AKT/mTOR signaling in cancer
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Molecular Biology Techniques and Applications
- Herpesvirus Infections and Treatments
- Lung Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Brain Metastases and Treatment
- AI in cancer detection
- Glycosylation and Glycoproteins Research
- Genomic variations and chromosomal abnormalities
- Medical Imaging and Pathology Studies
Centre Hospitalier de l’Université de Montréal
2013-2025
Université de Montréal
2002-2025
University of Toronto
2009-2017
Yale University
2016
University of Utah
2016
Vanderbilt University
2016
Calgary Laboratory Services
2016
University of Calgary
2016
Intermountain Medical Center
2016
Johns Hopkins University
2016
Background Breast cancer is the most common malignancy among women worldwide in terms of incidence and mortality. About 10% North American will be diagnosed with breast during their lifetime 20% those die disease. a heterogeneous disease biomarkers able to correctly classify patients into prognostic groups are needed better tailor treatment options improve outcomes. One powerful method used for biomarker discovery sample screening mass spectrometry, as it allows direct comparison protein...
Breast cancer is a heterogeneous disease, which comprises several molecular and genetic subtypes, each with characteristic clinicobiologic behavior imaging patterns. Traditional classification of breast based on the histopathologic features but offers limited prognostic value. Novel characterization cellular markers has allowed new that value, predictive categories disease aggressiveness. These signatures also open door to personalized therapeutic options, receptor-targeted therapies. For...
Objectives: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) 2 (HER2), approved in treatment HER2 positive breast cancer. Since EGFR overexpression has also been seen prostate cancer appears to correlate with worse clinical outcome, may represent novel therapeutic strategy This Phase II multicenter trial first evaluate early stage, hormonally untreated recurrent or metastatic Methods: Eligible patients received lapatinib...
PD-L1 expression is used to predict NSCLC response ICIs, but its performance suboptimal. The impact of KRAS mutations in these patients unclear. Studies evaluating co-mutations TP53, STK11 and KEAP1 as well the NLR showed that they may benefit ICIs.
Hematoxylin and eosin (H&E) staining is a well-established technique in histopathology. However, immunohistochemistry (IHC) interpretation done exclusively with hematoxylin counterstaining. Our goal was to investigate the potential of H&E as counterstaining (H&E-IHC) allow for visualization marker while confirming diagnosis on same slide. The quality immunostaining fast-technical performance were main criteria select final protocol. We stained multiple diagnostic tissues class I IHC tests...
BackgroundPreviously, we found that amplification of chromosome 17q24.1-24.2 is associated with lymph node metastasis, tumour size, and lymphovascular invasion in invasive ductal carcinoma. A gene within this amplicon, CACNG4, an L-type voltage-gated calcium channel gamma subunit, elevated breast cancers poor prognosis. Calcium homeostasis achieved by maintaining low intracellular levels. Altering influx/efflux mechanisms allows cells to maintain despite high serum levels often advanced...
Abstract Almost all genomic studies of breast cancer have focused on well-established tumours because it is technically challenging to study the earliest mutational events occurring in human epithelial cells. To address this we created a unique dataset samples ductoscopically obtained from ducts leading carcinomas and matched opposite side nipple. Here, demonstrate that perturbations mRNA abundance, with increasing proximity tumour, cannot be explained by copy number aberrations. Rather,...
We aimed to characterise a large cohort of non-invasive, human papillomavirus (HPV) and p53-independent verruciform lesions, such as 'vulvar acanthosis with altered differentiation' (VAAD), 'differentiated exophytic vulvar intra-epithelial lesion' (DEVIL) 'verruciform lichen simplex chronicus' (vLSC).From January 2008 December 2020 we retrospectively identified 36 eligible patients non-invasive lesions (n = 36) collected clinical, histological follow-up parameters. Verruciform occurred at...
Ectopic breast is found to occur most commonly in the axilla, but also less on vulva and sites outside “milk line” like face, neck chest. Vulvar adenofibroma developing ectopic tissue exceptionally rare. More precisely, vulvar associated with adenoma lactating changes has only been documented three times our knowledge. We herein report a mass specimen consistent fibroadenoma occurring 36-year-old woman postpartum period.
Radiotherapy (RT) is one of the four pillars cancer treatment. Plesiotherapy, or contact brachytherapy, involves irradiating a tumor by placing small radioactive sources directly on skin's surface above tumor. In this study, we evaluated efficacy novel local external radiation technique using iodine-125 seeds enclosed within 3D-printed case, positioned externally surface. First, protocol was tested skin NodRag1 mice with doses up to 10 Gy (at skin), and results demonstrated no signs...
Alterations in c-MET, a tyrosine kinase receptor encoded by the MET gene, have been reported approximately 3% of non-small cell lung cancer (NSCLC) cases and carry important treatment implications. The best studied genetic alterations are exon 14 skipping gene amplification; however, rearrangement has also described, multiple fusion partners reported. Recently, METex14-mutated NSCLC, multitarget inhibitors (TKIs), such as crizotinib cabozantinib, well MET-selective TKIs, tepotinib...
Abstract Background Patients with triple-negative breast cancer (TNBC) develop early recurrence. While PARP inhibitors (PARPi) have demonstrated potential in BRCA1/2 -mutant (BRCA MUT ) TNBC, durable responses will likely be achieved if PARPi are used combination. It is plausible that sequential administration of a potent like talazoparib combination carboplatin can enhance primary tumour and metastasis inhibition BRCA wild-type WT TNBCs, decrease toxicity. Methods We evaluated the impact...
The role of mitochondrial DNA (mtDNA) mutations in the development breast cancer is largely unknown. In this study, we investigated frequency and pattern D310 region, most commonly mutated region mtDNA, a series lesions. Using capillary electrophoresis, genotyped sequence neoplastic epithelial cells from 23 patients with synchronous ductal carcinoma situ (DCIS) invasive (IDC), 26 IDC only 29 DCIS only. A majority (68.4%) (71.4%) lesions harbour different sequences compared their matched...
Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed death ligand 1 (PD-L1), protein (PD-1), T-Lymphocyte-associated antigen 4 (CTLA-4) inhibitors are now part standard care for advanced NSCLC. However, prognostic impact PD-L1 expression in setting remains unknown. Methods: Patients...
Abstract Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer. Several molecular alterations have been identified DCIS. Among them, cyclooxygenase 2 (COX-2) overexpression has shown 60% to 80% DCIS cases. Celecoxib a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2. In this study, we evaluated whether COX-2 inhibition by celecoxib can reduce incidence cancer and its progression invasive mouse model exhibiting similar phenotype human...
Background: Epidermal growth factor receptor (EGFR) is the most common oncogenic mutation in lung adenocarcinoma and tyrosine kinase inhibitors (TKIs) have been considered standard treatment for more than a decade. However, time to initiation of TKIs (TTIT) from diagnosis often delayed represents challenge clinicians. We aimed assess impact TTIT on clinical outcomes complications. Method: was defined as between confirmed advanced TKI. Complications during this pre-TKI period were...